INTRODUCTION
============

Primary administration of systemic chemotherapy is standard of care for locally advanced breast cancer (LABC) [@B1]. In women with large operable tumors, preoperative administration might increase the likelihood of breast-conserving surgery [@B2]. Several randomized trials comparing preoperative versus postoperative treatment have shown equivalent disease-free survival (DFS) and overall survival (OS) [@B3]. Although pathologic stage may not correlate perfectly with DFS and OS, the value of findings from preoperative chemotherapy outweighs this disadvantage. Preoperative treatment serves as an excellent in vivo model, providing prognostic and potentially predictive information and facilitating the evaluation of tumor biomarkers to improve individualization of therapeutic strategies [@B4]. This may expedite the clinical development of new drugs and regimens.

Pathologic response and clinical outcomes
-----------------------------------------

Pathologic complete response (pCR) is associated with long-term survival [@B2],[@B5]-[@B9]. However, despite its value as a surrogate marker, pCR has some limitations as an endpoint because of the variety in definitions between studies [@B10]. An international panel recommended that pCR must not include any residual invasive or in situ cancer in the breast or lymph nodes [@B1], but it has been argued that such a restrictive and purist definition weakens the clinical utility of this endpoint and diminishes the number of informative patients [@B11].

An interesting concept with important clinical implications is the attainment of significant tumor downsizing to microscopic levels only. Patients with small (T1a-b), node-negative breast tumors have excellent rates of long-term relapse-free survival (91% at 10 years and 87% at 20 years) [@B12]. Measurement of residual breast cancer burden (RCB) has also been proposed as a practical alternative to the traditional dichotomy between pCR and residual disease to predict survival after preoperative chemotherapy (Figure [1](#F1){ref-type="fig"}) [@B13],[@B14]. The combination of RCB-0 (pCR or American Joint Committee on Cancer stage 0 [@B15]) and RCB-I (near pCR \[npCR\]) expands the subset of patients shown to benefit from preoperative chemotherapy. Achievement of pCR or npCR is associated with long DFS, whereas moderate or extensive residual disease predicts for short DFS. Based on these data, reduction of the initial tumor size to T1a is used to define npCR in the Xeloda in NeoAdjuvant (XeNA) study of preoperative chemotherapy described below.

Capecitabine plus docetaxel for early BC
----------------------------------------

Adding a taxane to anthracycline-based preoperative chemotherapy significantly improves overall response rates (ORR) and pCR rates [@B8],[@B16]. Combinations of capecitabine and a taxane are highly active in metastatic breast cancer (MBC) [@B17] and provide a promising non-anthracycline-based alternative for patients with early breast cancer with the advantage of potentially less cardiotoxicity [@B18].

Capecitabine is an oral fluoropyrimidine designed to deliver 5-fluorouracil (5-FU) selectively to tumor sites by exploiting higher concentrations of thymidine phosphorylase (TP) in malignant cells compared with normal cells [@B19]. TP activity is upregulated by several chemotherapeutic agents, including taxanes, providing an elegant explanation for the preclinical synergy between capecitabine and docetaxel [@B20]-[@B22]. TP expression may also be a predictive marker for the clinical benefit of docetaxel plus capecitabine in patients with breast cancer [@B23].

In a randomized trial in patients with MBC, the combination of capecitabine 1250 mg/m^2^twice daily (BID) on days 1-14 plus docetaxel 75 mg/m^2^ on day 1 (XT) significantly improved OS (hazard ratio, 0.775; 95% confidence interval \[CI\], 0.634-0.947) compared with docetaxel alone [@B17]. Gastrointestinal side effects and hand-foot syndrome were more common with XT, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more common with single-agent docetaxel. Based on clinical experience and findings from retrospective analyses of dose modification in this trial, lower doses of capecitabine and docetaxel are typically used in this setting and do not appear to reduce efficacy [@B24],[@B25]. The high activity and manageable safety profile of XT given at appropriate doses in the metastatic setting provided the rationale for evaluating XT in early breast cancer [@B26].

In a phase III trial, 209 women with axillary node-positive, stage II/III breast cancer were randomly allocated to receive four 3-weekly cycles of preoperative XT (capecitabine 1000 mg/m^2^ BID on days 1-14 and docetaxel 75 mg/m^2^ on day 1) or AC (doxorubicin 60 mg/m^2^ and cyclophosphamide 600 mg/m^2^ on day 1) [@B18]. XT significantly increased pCR rate (21% vs. 10%, respectively, *P* = 0.024) and ORR (84% vs. 65%, respectively, *P* = 0.003). Of note, the pCR rate achieved with XT was within the range seen with anthracycline-taxane sequential therapy in a mixed population of patients (human epidermal growth factor receptor \[HER\]2 negative and positive) [@B8]. Since most of the published preoperative trials used 6 or 8 cycles of treatment, it was considered important to explore the activity of a shorter treatment course (4 cycles) for both HER2-positive and HER2-negative patients.

Capecitabine, docetaxel, plus trastuzumab for HER2-positive BC
--------------------------------------------------------------

Non-anthracycline preoperative regimens are a particularly interesting proposition in HER2-positive breast cancer, because they avoid the risk of anthracycline-induced cardiotoxicity in patients eligible for adjuvant or preoperative trastuzumab. The value of preoperative trastuzumab plus chemotherapy has been demonstrated in several phase II studies [@B9],[@B27]-[@B31]. In 42 patients with operable breast cancer, adding trastuzumab to preoperative paclitaxel followed by 5-FU, epirubicin, and cyclophosphamide significantly improved pCR rate compared with chemotherapy alone (67% vs. 25%, respectively; *P* = 0.02) [@B30].

In vivo data [@B32] and clinical studies [@B33]-[@B35] have demonstrated the efficacy of trastuzumab plus capecitabine in HER2-positive breast cancer. A randomized phase II study in patients with MBC or LABC compared 3-weekly cycles of HXT (trastuzumab 8 mg/kg loading dose followed by 6 mg/kg, capecitabine 950 mg/m^2^ BID days 1-14, and docetaxel 75 mg/m^2^) with HT (trastuzumab and docetaxel 100 mg/m^2^) [@B36]. Both combinations produced high ORR (71% and 73%, respectively), but the HXT combination significantly prolonged both time to progression and progression-free survival compared with HT, with the median increased by 5 months for both parameters. Promising results were also observed in a phase II study of preoperative HXT (trastuzumab, capecitabine 900 mg/m^2^ BID, and docetaxel 36 mg/m^2^days 1 and 8) administered every 3 weeks to patients with HER2-positive LABC (or XT alone for patients with HER2-negative tumors) [@B37]. The ORR was 94% and, in patients treated with HXT, the pCR rate was 45%. HXT demonstrated good tolerability in these studies: the lower XT dose is well tolerated, and HXT may reduce the risk of overlapping cardiac toxicity with adjuvant anthracyclines.

XeNA
====

This open-label, multicenter, phase II study uses Simon\'s optimal two-stage design [@B38] to independently assess the efficacy of preoperative XT in HER2-negative and HXT in HER2-positive breast cancer. The study design was approved by the ethics committees at participating institutions, and all patients provided written informed consent. Enrollment of 157 patients was completed in May 2007; 156 patients (122 HER2-negative and 34 HER2-positive) are evaluable.

Patient Population
------------------

Women ≥18 years with newly diagnosed, histologically confirmed, infiltrating (invasive), HER2-negative or HER2-positive stage II/III breast cancer, with no evidence of metastatic disease except ipsilateral axillary lymph nodes (T2-3, N0-1, M0), were eligible for the study provided that they had not previously received any type of systemic or local primary treatment for breast cancer. To facilitate response assessment, patients were required to have a clinically palpable tumor of \>2 cm, meeting the Response Evaluation Criteria for Solid Tumors (RECIST) for palpable measurable disease. Key exclusion criteria included inflammatory breast cancer, clinically significant cardiac disease, and inadequate renal function.

Treatments
----------

All eligible patients received four 21-day cycles of capecitabine 825 mg/m^2^ BID on days 1-14 plus docetaxel 75 mg/m^2^ on day 1. This dosing regimen was selected on the basis of previous clinical studies of XT suggesting that doses can be reduced to improve tolerability without adversely affecting efficacy [@B24],[@B26]. Patients with HER2-positive tumors determined by fluorescence in situ hybridization (FISH) also received a trastuzumab 4 mg/kg loading dose (90-minute infusion) on day 1 followed by 2 mg/kg weekly (30-minute infusion) for 11 doses (Figure [2](#F2){ref-type="fig"}). An Independent Data Monitoring Board evaluated the safety and initial efficacy after treatment of a predetermined number of patients. Based on their analysis of the data, the trial was allowed to continue with no change to treatment doses and schedules; a change in the efficacy endpoint to pCR plus npCR was suggested.

Primary and Secondary End Points
--------------------------------

The primary endpoint for the study was the rate of pCR plus npCR (residual T1a) in the affected breast after 4 cycles of preoperative therapy, determined by pathologic assessment of the resected specimen at the time of definitive surgery. A hematoxylin and eosin stained slide from each of the paraffin blocks prepared from the breast tissue and lymph nodes was reviewed at a central laboratory (Albany Medical College Department of Pathology and Laboratory Medicine, New York, NY) to establish the presence or absence of infiltrating breast cancer. Absence of histological evidence of invasive breast cancer cells defined pCR; npCR was defined as the presence of invasive tumor ≤5 mm (T1a). While pCR and npCR appear to have equivalent power to predict long-term survival [@B13], the sum of these endpoints has the advantage of providing a greater number of informative events, which is a particularly important consideration for the complementary correlative studies described below.

Secondary clinical endpoints defined for the study included pCR and npCR as individual efficacy parameters, ORR (according to RECIST), rates of local recurrence, DFS, OS, safety profile (assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0), and quality of life (measured by the Functional Assessment of Cancer Therapy - Breast before, during, and at the completion of preoperative therapy).

Correlative Studies
-------------------

Blood and tissue biomarker levels and candidate gene expression were measured prior to preoperative therapy and at the time of surgery to identify predictive factors associated with pathologic response to XT or HXT. Potential biomarkers include TP, thymidine synthase (TS), and dihydropyrimidine dehydrogenase (DPD) for capecitabine and Tau protein for taxanes. Circulating tumor cell (CTC) levels were determined using the CellSearch System (Veridex, LLC., Warren, NJ) prior to the first treatment cycle and prior to definitive surgery in patients with HER2 positive tumors. An interim analysis confirmed that CTCs were detectable in patients in this study. Microarray analysis (AmpliChip p53 test; Roche Diagnostics, Indianapolis, IN) was used to measure p53 gene mutation levels in tissue samples prior to treatment. Preliminary data showed that approximately half of patients expressed p53 mutations at diagnosis.

Interim Analysis
----------------

Baseline characteristics of 90 patients included in an interim analysis are shown in Table [1](#T1){ref-type="table"} [@B39]. The clinical response rates were 79% in HER2-negative and 90% in HER2-positive breast cancer. The rate of pCR plus npCR was 52% in patients with HER2-positive BC. After four treatment cycles, mean tumor diameters were reduced by 55% and 61%, respectively, in the HER2-negative and HER2-positive groups. The most frequent adverse events were hematologic toxicities and hand-foot syndrome. There were no grade 4 adverse events, treatment-related deaths, or clinical or subclinical cardiac events. Treatment was discontinued because of toxicity in 15 patients (10%) and four patients progressed prior to surgery.

CONCLUSIONS
===========

XT and HXT are promising non-anthracycline regimens for the preoperative treatment of women with HER2-negative and HER2-positive breast cancer, respectively. The ongoing XeNA study, in which treatment was assigned based on centrally performed FISH analysis, is expected to provide further clinical evidence to support the high activity observed with these regimens in patients with LABC or MBC [@B17],[@B36]. A particularly important feature of the XeNA study is the use of pCR [plus]{.ul} npCR as the primary endpoint. This endpoint is justified by previous data showing that patients with T1a tumors have excellent long-term survival [@B12] and that pCR and npCR have equivalent predictive power [@B13]. In addition, by increasing the number of informative events, the sum of pCR and npCR will facilitate correlative studies designed to identify patients most likely to benefit from XT and HXT and may expedite the clinical evaluation of these novel preoperative regimens. The final analysis, including data from these correlative studies specifically designed to identify predictive biomarkers associated with pathologic response, will be available in 2009.

The XeNA study is sponsored by Roche, Nutley, NJ, USA. Medical writing support was provided by Tim Kelly for Insight Medical Communications, Inc., a division of Grey Healthcare Group, on behalf of Roche, Nutley, NJ, USA.
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Characteristics of patients included in an interim analysis.

  Baseline characteristics     HER2-negative (N=67)   HER2-positive (N=23)
  ---------------------------- ---------------------- ----------------------
  Median age, years (range)    52 (29-82)             52 (32-66)
  Estrogen receptor positive   44 (65%)               10 (43%)
  Mean tumor diameter, cm      5.5                    5.6
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